Dr. Reddy's Labs

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- #DrReddys--Dr.

Dr. Reddy's Laboratories received approval of XEGLYZE™ (abametapir) lotion, 0.74%, in the U.S.  

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd.

Dr. Reddy's to release Q1 FY 21 results on July 29th, 2020

AbbVie

Horizon Pharma

Eli Lilly

Novo Nordisk

United Therapeutics

Zoetis

There’s a select group of pharmaceutical stocks that stand to win without even looking for a Covid-19 cure.
The post The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase appeared first on InvestorPlace.

The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase

Dr. Reddy's (RDY) signs agreement with FUJIFILM Toyama Chemical and Global Response Aid for Avigan tablets for the potential treatment of COVID-19.

Dr. Reddy's Inks Deal With Two Companies for Coronavirus Drug

In May, the Food and Drug Administration approved as many as 13 new drugs, higher than the eight approved in the same month last year.

3 Stocks to Buy on New Drug Approvals by FDA

AECOM

Allegheny Technologies

Bill.com

BorgWarner

China Unicom

Consolidated Communications Holdings

Everbridge

Focus Financial Partners

ManTech

NetEase

Patterson Companies

Pool

Pure Storage

United Natural Foods

Veoneer Inc

Werner Enterprises

Workiva

Woodward

To hear some tell it, bigger is always better on Wall Street.

19 of the Best Stocks You've Never Heard Of

Gilead Sciences

Dr. Reddy Laboratories (RDY) inks a deal with Gilead to register, manufacture and sell the latter's Remdesivir ??? a potential treatment for COVID-19?

Dr. Reddy's Inks Deal With Gilead Sciences for Remdesivir

Grifols, S.A.

Johnson & Johnson

Merck

Repligen

Takeda Pharmaceutical

Much of the conversation about pharmaceutical stocks rests on the coronavirus, but these high-growth names have potential beyond the pandemic.

7 Pharmaceutical Stocks to Buy for Post-Pandemic Gains

Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.

Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat

Dr. Reddy's Laboratories' (RDY) CEO Erez Israeli on Q4 2020 Results - Earnings Call Transcript

An Indian manufacturer of generic prescription drugs can accomplish what American counterparts cannot. Here's why.

Is Dr. Reddy's Laboratories a Buy?

Does Doctor Reddy's (RDY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Doctor Reddy's (RDY) is a Great Choice

Bull of the Day: Dr. Reddy's Laboratories (RDY)

FTI Consulting

Rocky Brands

Sprouts Farmers Markets

Stamps.com

A portfolio of low-beta stocks can protect your investments from the coronavirus-induced market volatility.

Beat Coronavirus Blues With These 5 Low-Beta Stocks

What Makes Doctor Reddy's (RDY) a Strong Momentum Stock: Buy Now?

As of late, it has definitely been a great time to be an investor Dr. Reddy's Laboratories

Will Dr. Reddy's Laboratories Continue to Surge Higher?

Dr. Reddy's (RDY) earnings (excluding impairment charge) increase year over year in the third quarter of fiscal 2020.

Dr. Reddy's (RDY) Q3 Earnings and Revenues Increase Y/Y

Dr. Reddy's Laboratories Ltd (RDY) CEO Erez Israeli on Q3 2020 Results - Earnings Call Transcript

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.

Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y

Dr. Reddy's Laboratories Ltd (RDY) CEO Erez Israeli on Q2 2020 Results - Earnings Call Transcript

Azure Power Global

WNS Holdings Ltd

The government of India unveils an array of concessions to spur the economy. This in turn will slash most corporate taxes to 22% while new manufacturers will pay even a lower corporate tax rate of 15%.

Is it Apt to Foray Into the Indian Stock Market?: An Analysis

Clean Harbors

DaVita

Luna Innovations

We have shortlisted solid stocks from the top-performing sectors in Q2 that should make a great addition to your portfolio.

5 Stocks From the Best Performing Sectors in Q2

Anglogold Ashanti Plc

Delta Air Lines

Energy Transfer LP Unit

Federated Investors

We have highlighted some stock-picking ideas from the top-ranked cohort that could prove extremely beneficial for investors by reducing the risk of a downside.

5 Stock-Picking Strategies to Counter Market Turbulence

Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.

Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y

Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.

Dr. Reddy's Inks Deal to Sell Neurology Branded Products

News for Dr. Reddy's Labs Stock (RDY)